Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn

 
• By Sten Stovall

Bristol-Myers Squibb has joined the big pharma trend of divesting non-core assets to focus on high-margin prescription drugs by agreeing to sell over-the-counter drugs business UPSA for $1.6bn to Japanese healthcare firm Taisho Pharmaceutical.

Store shelving
Buying OTC Unit UPSA From BMS will complement Taisho’s product portfolio • Source: Shutterstock

More from Deals

More from Business